Analysts Set Becton, Dickinson and Company (NYSE:BDX) Price Target at $182.20

Becton, Dickinson and Company (NYSE:BDX) has been given a consensus recommendation of “Hold” by the seventeen analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $185.00.

A number of equities analysts recently issued reports on the company. TD Cowen boosted their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. The Goldman Sachs Group reduced their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 27th. UBS Group assumed coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price for the company. Weiss Ratings restated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Finally, Bank of America reduced their price target on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. This trade represents a 7.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 7,627 shares of company stock valued at $1,206,549. Corporate insiders own 0.40% of the company’s stock.

Hedge Funds Weigh In On Becton, Dickinson and Company

Institutional investors have recently made changes to their positions in the company. Crux Wealth Advisors lifted its holdings in shares of Becton, Dickinson and Company by 0.8% during the 4th quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier’s stock valued at $1,222,000 after purchasing an additional 49 shares during the last quarter. Larson Financial Group LLC grew its stake in Becton, Dickinson and Company by 1.7% during the 4th quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock worth $627,000 after buying an additional 53 shares during the last quarter. Camelot Portfolios LLC increased its position in Becton, Dickinson and Company by 1.5% during the 4th quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock valued at $688,000 after buying an additional 54 shares in the last quarter. McElhenny Sheffield Capital Management LLC raised its stake in Becton, Dickinson and Company by 3.6% in the fourth quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier’s stock valued at $309,000 after buying an additional 55 shares during the last quarter. Finally, Atlantic Union Bankshares Corp boosted its holdings in Becton, Dickinson and Company by 0.9% in the fourth quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock worth $1,185,000 after acquiring an additional 57 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $183.14 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The firm has a market capitalization of $50.46 billion, a P/E ratio of 55.16, a price-to-earnings-growth ratio of 12.79 and a beta of 0.19. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The company’s 50-day moving average is $156.55 and its 200 day moving average is $161.69.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.84% and a net margin of 4.52%.The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.